Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor.
Roymans, D., Alnajjar, S.S., Battles, M.B., Sitthicharoenchai, P., Furmanova-Hollenstein, P., Rigaux, P., Berg, J.V.D., Kwanten, L., Ginderen, M.V., Verheyen, N., Vranckx, L., Jaensch, S., Arnoult, E., Voorzaat, R., Gallup, J.M., Larios-Mora, A., Crabbe, M., Huntjens, D., Raboisson, P., Langedijk, J.P., Ackermann, M.R., McLellan, J.S., Vendeville, S., Koul, A.(2017) Nat Commun 8: 167-167
- PubMed: 28761099 
- DOI: 10.1038/s41467-017-00170-x
- Primary Citation of Related Structures:  
5KWW - PubMed Abstract: 
Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today ...